title: Systematic review and meta-analysis of somatostatin analogues in the prevention of postoperative complication after pancreaticoduodenectomy.
abstract: BACKGROUND
  The use of somatostatin analogues (SAs) following pancreaticoduodenectomy (PD) is controversial.
  
  
  METHODS
  Literature databases were searched systematically for relevant articles. A meta-analysis of all randomized controlled trials (RCTs) evaluating prophylactic SAs in PD was performed.
  
  
  RESULTS
  Fifteen RCTs involving 1,352 patients were included. There was a towards reduced incidences of pancreatic fistulas (p = 0.26), clinically significant pancreatic fistulas (p = 0.08), and bleeding (p = 0.05) in prophylactic SAs group. In subgroup analyses, prophylactic somatostatin significantly reduced the incidence of pancreatic fistulas(p = 0.02), with a nonsignificant trend toward reduced incidence of clinically significantly pancreatic fistulas (p = 0.06).Pasireotide significantly reduced the incidence of clinically significantly pancreatic fistulas (p = 0.03). Octreotide had no influence on the incidence of pancreatic fistulas.
  
  
  CONCLUSIONS
  The current best evidence suggests prophylactic treatment with somatostatin or pasireotide has a potential role in reducing the incidence of pancreatic fistulas, while octreotide had no influence on the incidence of pancreatic fistulas.High-quality RCTs assessing the role of somatostatin and pasireotide are required for further verification.
authors: Kaizhou
authors: K
authors: Jin
authors: Haiyang
authors: H
authors: Zhou
authors: Jian
authors: J
authors: Zhang
authors: Weijun
authors: W
authors: Wang
authors: Yanping
authors: Y
authors: Sun
authors: Canping
authors: C
authors: Ruan
authors: Zhiqian
authors: Z
authors: Hu
authors: Yi
authors: Y
authors: Wang
mesh_terms: D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015233:Models, Statistical; D015282:Octreotide / Q000627:therapeutic use*; D010185:Pancreatic Fistula / Q000209:etiology / Q000517:prevention & control*; D016577:Pancreaticoduodenectomy; D011183:Postoperative Complications / Q000517:prevention & control*; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D013004:Somatostatin; C517782:pasireotide; D015282:Octreotide